Gregory Behbehani
Hematology · Columbus, OHNPI 1053679217
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,000 of the $9,915 with a category attached, or 60.5%. 3 manufacturers reported payments, led by Agios Pharmaceuticals, Inc. at 40.0% of the total. Reporting peaked in 2020 at $3,969 and has fallen 66.7% since, to $1,321 in 2025. That places this record below the midpoint for hematology clinicians in OH, where the typical reported total is $9,915.
Across 23 payments — averaging $431.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$4K
- Jazz Pharmaceuticals Inc.$3K
- Adaptive Biotechnologies Corporation$2K
Across 20 payments — averaging $71,015 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$930K
- Sanofi US Services Inc.$490K
What the payments were for
- Consulting fees$6,00061%
- Travel & lodging$3,45135%
- Food & beverage$4635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 8 | $3,969 |
| Jazz Pharmaceuticals Inc. | 3 | $3,471 |
| Adaptive Biotechnologies Corporation | 12 | $2,475 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,915 in reported general payments places this provider in the 50th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 32 | $1,094,493 |
| TibsovoIvosidenib | 21 | $670,418 |
| XospataGilteritinib Fumarate | 20 | $280,387 |
| BosulifBosutinib | 12 | $226,357 |
| InqoviDecitabine/Cedazuridine | 11 | $92,748 |
| Imatinib Mesylate | 14 | $54,976 |
| VenclextaVenetoclax | 25 | $39,310 |
| Hydroxyurea | 19 | $184 |
| Ondansetron Hcl | 18 | $117 |
| Acyclovir | 14 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.